Gastroesophageal Reflux Disease clinical trials

Explore recruiting gastroesophageal reflux disease clinical trials.

Recruiting gastroesophageal reflux disease studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Gastroesophageal Reflux Disease trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 2 to 11 Years With Symptomatic Nonerosive Gastroesophageal Reflux Disease

Poland

Therapeutic exploratory (Phase II) EU CTIS Study details

Treatment of Gastroesophageal Reflux Disease in Infants- a Randomized Controlled Trial

Denmark

Phase III and phase IV (Integrated) EU CTIS Study details

A Phase I trial to investigate the pharmacokinetics and ECG effects of single doses of linaprazan glurate administered as oral tablets to healthy participants

Sweden

Human Pharmacology (Phase I)- Other EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter clinical trial to evaluate the efficacy and safety of linaprazan glurate compared to lansoprazole in maintenance of healing in participants with healed erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Hungary, Germany, Romania, Bulgaria, Czechia, Poland

Therapeutic confirmatory (Phase III) EU CTIS Study details

A randomized, phase 3, double-blind, double-dummy, active comparator-controlled multicenter study to evaluate the efficacy and safety of 2 doses of linaprazan glurate compared to lansoprazole in 4 or 8 weeks healing in participants with erosive esophagitis (EE) due to gastroesophageal reflux disease (GERD) of Los Angeles (LA) grades A to D

Germany, Poland, Hungary, Bulgaria, Romania, Czechia

Therapeutic confirmatory (Phase III) EU CTIS Study details

Gastroesophageal Reflux Disease trials by city

Gastroesophageal Reflux Disease in Toronto Gastroesophageal Reflux Disease in Vancouver Gastroesophageal Reflux Disease in Montreal Gastroesophageal Reflux Disease in Calgary Gastroesophageal Reflux Disease in Edmonton Gastroesophageal Reflux Disease in Ottawa Gastroesophageal Reflux Disease in Winnipeg Gastroesophageal Reflux Disease in Quebec City Gastroesophageal Reflux Disease in Hamilton Gastroesophageal Reflux Disease in Kitchener Gastroesophageal Reflux Disease in London Gastroesophageal Reflux Disease in Halifax Gastroesophageal Reflux Disease in New York Gastroesophageal Reflux Disease in Los Angeles Gastroesophageal Reflux Disease in Chicago Gastroesophageal Reflux Disease in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease